These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21873938)

  • 1. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study.
    Karidis NP; Giaginis C; Tsourouflis G; Alexandrou P; Delladetsima I; Theocharis S
    Med Sci Monit; 2011 Sep; 17(9):BR257-65. PubMed ID: 21873938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
    Giaginis C; Alexandrou P; Poulaki E; Delladetsima I; Troungos C; Patsouris E; Theocharis S
    Pathol Oncol Res; 2016 Apr; 22(2):269-75. PubMed ID: 26220827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.
    Giaginis C; Tsourouflis G; Zizi-Serbetzoglou A; Kouraklis G; Chatzopoulou E; Dimakopoulou K; Theocharis SE
    Pathol Oncol Res; 2010 Jun; 16(2):267-76. PubMed ID: 19949912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
    Theocharis S; Klijanienko J; Giaginis C; Alexandrou P; Patsouris E; Sastre-Garau X
    Pathol Oncol Res; 2014 Apr; 20(2):277-84. PubMed ID: 24022400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
    Giaginis C; Michailidi C; Stolakis V; Alexandrou P; Tsourouflis G; Klijanienko J; Delladetsima I; Theocharis S
    Med Sci Monit; 2011 Feb; 17(3):BR81-90. PubMed ID: 21358597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
    Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
    J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.
    Giaginis C; Alexandrou P; Delladetsima I; Giannopoulou I; Patsouris E; Theocharis S
    Tumour Biol; 2014 Jan; 35(1):61-71. PubMed ID: 23873102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
    Giaginis C; Alexandrou P; Delladetsima I; Karavokyros I; Danas E; Giagini A; Patsouris E; Theocharis S
    Pathol Oncol Res; 2016 Jan; 22(1):189-96. PubMed ID: 26498465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions.
    Lakiotaki E; Giaginis C; Tolia M; Alexandrou P; Delladetsima I; Giannopoulou I; Kyrgias G; Patsouris E; Theocharis S
    Biomed Res Int; 2015; 2015():839403. PubMed ID: 26539529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions.
    Giaginis C; Demetriou N; Alexandrou P; Stolakis V; Delladetsima I; Klijanienko J; Griniatsos I; Theocharis S
    Med Sci Monit; 2012 Apr; 18(4):BR123-9. PubMed ID: 22460085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eph-ephrin A system regulates human choriocarcinoma-derived JEG-3 cell invasion.
    Fujiwara H; Nishioka Y; Matsumoto H; Suginami K; Horie A; Tani H; Matsumura N; Baba T; Sato Y; Araki Y; Konishi I
    Int J Gynecol Cancer; 2013 Mar; 23(3):576-82. PubMed ID: 23429488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of farnesoid X receptor expression in thyroid neoplasia.
    Giaginis C; Tsoukalas N; Alexandrou P; Tsourouflis G; Dana E; Delladetsima I; Patsouris E; Theocharis S
    Future Oncol; 2017 Aug; 13(20):1785-1792. PubMed ID: 28762281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions.
    Giaginis C; Zarros A; Alexandrou P; Klijanienko J; Delladetsima I; Theocharis S
    APMIS; 2010 Mar; 118(3):210-21. PubMed ID: 20132187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.
    Michailidi C; Giaginis C; Stolakis V; Alexandrou P; Klijanienko J; Delladetsima I; Chatzizacharias N; Tsourouflis G; Theocharis S
    Pathol Oncol Res; 2010 Dec; 16(4):497-507. PubMed ID: 20405349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The expression and clinical significance of EphA2 and E-cadherin in papillary thyroid carcinoma].
    Liu Y; Miao Y; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jun; 29(11):1020-3. PubMed ID: 26536708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.
    Brantley-Sieders DM; Jiang A; Sarma K; Badu-Nkansah A; Walter DL; Shyr Y; Chen J
    PLoS One; 2011; 6(9):e24426. PubMed ID: 21935409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
    Saintigny P; Peng S; Zhang L; Sen B; Wistuba II; Lippman SM; Girard L; Minna JD; Heymach JV; Johnson FM
    Mol Cancer Ther; 2012 Sep; 11(9):2021-32. PubMed ID: 22807579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
    Giaginis C; Tsoukalas N; Bournakis E; Alexandrou P; Kavantzas N; Patsouris E; Theocharis S
    BMC Clin Pathol; 2014 Feb; 14(1):8. PubMed ID: 24495444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
    Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
    Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
    Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
    Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.